Soligenix Urges Stockholders to Vote at Annual Meeting

PRINCETON, N.J., May 29, 2024 - Soligenix, Inc. (Nasdaq: SNGX), a biopharmaceutical company in the advanced stages of developing treatments for rare diseases with unmet medical needs, is calling on its eligible shareholders to participate in the reconvened annual meeting scheduled for May 30, 2024. The company emphasizes the importance of shareholder participation and encourages all eligible shareholders to exercise their voting rights immediately.

Those eligible to vote can do so by reaching out to the company's proxy solicitor, Alliance Advisors, at 1-833-782-7145. Eligibility to vote is determined based on share ownership as of the close of business on April 10, 2024. Importantly, even those who owned shares as of the record date but have since sold them are still entitled to vote.

Shareholders are advised to review the official proxy materials, which provide detailed information on each proposal to be voted on. These materials were filed with the SEC and can be accessed online.

The materials related to the annual meeting serve as solicitation material, and in connection with this, Soligenix has filed a definitive proxy statement and a proxy card with the SEC as of April 29, 2024. Shareholders are strongly advised to read these documents, along with any amendments, supplements, or other relevant filings, before making any voting decisions. These documents contain crucial information about the proposals and can be accessed free of charge on the SEC's website.

The company, its directors, nominees for directorships, certain officers, and other employees are considered "participants" in the proxy solicitation process. Further details about these participants, their interests, and their security holdings are disclosed in the definitive proxy statement filed on April 29, 2024, and any changes in these holdings are reported through Forms 3, 4, or 5 filed with the SEC. All these documents are available at no cost on the SEC's website.

Soligenix’s business focuses on two main segments: Specialized BioTherapeutics and Public Health Solutions. In the Specialized BioTherapeutics segment, the company is working on HyBryte™ (SGX301), a photodynamic therapy using visible light for cutaneous T-cell lymphoma (CTCL). Following the success of the second Phase 3 study, Soligenix aims to gain regulatory approvals to support global commercialization.

Other development programs in this segment include synthetic hypericin (SGX302) for psoriasis, dusquetide (SGX942) for inflammatory diseases like oral mucositis in cancer patients, and SGX945 for Behçet's Disease.

In its Public Health Solutions segment, Soligenix is developing RiVax®, a vaccine for ricin toxin, and vaccines targeting viruses like Marburg, Ebola, and COVID-19 under the CiVax™ program. The company's proprietary heat stabilization technology, ThermoVax®, is integral to these vaccine programs, which have been supported by funding from various government agencies including NIAID, DTRA, and BARDA.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!